The marine‐derived furanone reduces intracellular lipid accumulation in vitro by targeting LXRα and PPARα

Recent studies have demonstrated that commercially available lipid‐lowering drugs cause various side effects; therefore, searching for anti‐hyperlipidaemic compounds with lower toxicity is a research hotspot. This study was designed to investigate whether the marine‐derived compound, 5‐hydroxy‐3‐met...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2020-03, Vol.24 (6), p.3384-3398
Hauptverfasser:	Li, Ting, Hu, Shu‐Mei, Pang, Xiao‐Yan, Wang, Jun‐feng, Yin, Jia‐Yu, Li, Fa‐Hui, Wang, Jin, Yang, Xiao‐Qian, Xia, Bin, Liu, Yong‐Hong, Song, Wei‐Guo, Guo, Shou‐Dong
Format:	Artikel
Sprache:	eng
Schlagworte:	acetyl‐CoA carboxylase Animals Antagonists ATP-Binding Cassette Transporters - metabolism Cancer Cell culture Cell Line, Tumor Cholesterol Cytotoxicity Dyslipidemia Enzymes fatty acid synthase Fatty acids furanone Hep G2 Cells Humans Hyperlipidemias - drug therapy Hypolipidemic Agents - adverse effects Hypolipidemic Agents - pharmacology Lipid Metabolism - drug effects Lipids Lipids - analysis Lipoproteins Lipoproteins, LDL - analysis Liver Liver X receptors Liver X Receptors - antagonists & inhibitors Liver X Receptors - metabolism Low density lipoprotein Low density lipoprotein receptors LXR antagonist Medical research Metabolic disorders Metabolism Metabolites Mice Oleic acid Original Polyclonal antibodies PPAR alpha - antagonists & inhibitors PPAR alpha - metabolism PPAR antagonist PPARα agonist Proteins RAW 264.7 Cells Receptor density Regulation reverse cholesterol transport Statins Sterols Triglycerides - analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!